Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.58 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.58 |
| ▸ | ACACB | O00763 | 7/20 | 0.51 |
| ▸ | PLK1 | P53350 | 1/20 | 0.46 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30132213 | 0.86 | ACACB (0.51) | ACACB | |
| SCHEMBL255199 | 0.84 | GRM5 (0.51) | ACACBLNPEP | |
| SCHEMBL403799 | 0.84 | GRM5 (0.51) | ACACBLNPEP | |
| SCHEMBL13654190 | 0.84 | GRM5 (0.51) | ACACBLNPEP | |
| SCHEMBL22769302 | 0.83 | TAS1R3 (0.45) | TAS1R3TAS1R1ACACB | |
| SCHEMBL22769341 | 0.83 | TAS1R3 (0.48) | TAS1R3TAS1R1ACACBLNPEP | |
| SCHEMBL22769301 | 0.83 | TAS1R3 (0.45) | TAS1R3TAS1R1ACACB | |
| SCHEMBL21258371 | 0.83 | TAS1R3 (0.48) | TAS1R3TAS1R1ACACBLNPEP | |
| SCHEMBL21258304 | 0.83 | TAS1R3 (0.48) | TAS1R3TAS1R1ACACBLNPEP | |
| SCHEMBL19262856 | 0.83 | TAS1R3 (0.45) | TAS1R3TAS1R1ACACBLNPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250099433-A1 | COMPOSITION AND METHOD FOR TREATMENT OF GRAM NEGATIVE BACTERIAL INFECTION | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2025-03-27 | — | — | US | disclosed |
| WO-2023015236-A2 | COMPOSITION AND METHOD FOR TREATMENT OF GRAM NEGATIVE BACTERIAL INFECTION | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2023-02-09 | — | — | WO | disclosed |
| WO-2023015236-A2 | COMPOSITION AND METHOD FOR TREATMENT OF GRAM NEGATIVE BACTERIAL INFECTION | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2023-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250099433-A1 | COMPOSITION AND METHOD FOR TREATMENT OF GRAM NEGATIVE BACTERIAL INFECTION | NR1H3, NR1H4, NR1H2 | TAS1R3 815/4885TAS1R1 1677/4885ACACB 3126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.